» Articles » PMID: 29122897

Polymyalgia Rheumatica Development in a Patient Under PI3K Inhibitor Therapy for Chronic Lymphocytic Leukaemia

Overview
Journal BMJ Case Rep
Specialty General Medicine
Date 2017 Nov 11
PMID 29122897
Authors
Affiliations
Soon will be listed here.
Abstract

We report a patient with chronic lymphocytic leukaemia (CLL) who was treated with idelalisib, a PI3Kδ inhibitor with rituximab. After 20 weeks of treatment, the patient developed classical signs and symptoms of polymyalgia rheumatica (PMR) in association with an elevated C reactive protein of 74 mg/L. After 2 weeks of prednisolone 15 mg daily symptoms had resolved and acute phase markers normalised. To our knowledge, this is the first report of PMR developing as a complication of PI3Kδ inhibitor treatment of CLL.

References
1.
Banerjee S, Brosnahan G . Polymyalgia rheumatica in a renal transplant patient. J Ark Med Soc. 2008; 105(5):115-7. View

2.
Macchioni P, Boiardi L, Catanoso M, Pulsatelli L, Pipitone N, Meliconi R . Tocilizumab for polymyalgia rheumatica: report of two cases and review of the literature. Semin Arthritis Rheum. 2013; 43(1):113-8. DOI: 10.1016/j.semarthrit.2013.01.003. View

3.
Bhatia A, Ell P, Edwards J . Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005; 64(7):1099-100. PMC: 1755553. DOI: 10.1136/ard.2005.036533. View

4.
Curran M, Montalvo W, Yagita H, Allison J . PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A. 2010; 107(9):4275-80. PMC: 2840093. DOI: 10.1073/pnas.0915174107. View

5.
Oke A, Sammut L, Hull R . Comment on: Musculoskeletal complication of haematological disease. Rheumatology (Oxford). 2016; 56(2):320-321. DOI: 10.1093/rheumatology/kew372. View